REVAMP: Management Guided by Genotypic Resistance Testing Following First-line ART Failure Comparable to Viral Load–Guided Management in Sub-Saharan Africa

March 6-10, 2021; Virtual
Study finds that use of genotypic resistance testing to guide management of patients experiencing first-line ART failure does not improve viral suppression rates, highlighting need for alternative strategies to improve management of ART failure.
Format: Microsoft PowerPoint (.ppt)
File Size: 183 KB
Released: March 8, 2021

Acknowledgements

Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Gilead Sciences
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Slides from CCO: Switching ART in HIV: 3-drug therapy, oral 2-drug options, long-acting injectable 2-drug regimens, single tablet regimens (STRs)

Daniel R. Kuritzkes, MD Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD Released: June 7, 2021

Slides from Daniel Kuritzkes and CCO. Switching to long-acting cabotegravir: ATLAS and FLAIR data, starting, dosing regimens, avoiding treatment failure

Daniel R. Kuritzkes, MD Released: June 4, 2021

Drs Roger Bedimo, Princy N. Kumar, and Brian Wood, answer commonly asked questions on managing heavily treatment-experienced patients with HIV

Roger Bedimo, MD, MS, FACP Princy N. Kumar, MD, FIDSA, MACP Brian Wood, MD Released: June 2, 2021

Download free CCO slides reviewing a patient case and key data and guidelines on weight gain in aging persons with HIV

Karine Lacombe, MD, PhD Released: May 27, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue